INTRODUCTION

Testicular cancer is the most prevalent solid neoplasia among men aged 18–39 years. Its incidence has almost doubled between 1971 and 2015, accounting for 7.06 per 100,000 individuals in Canada. Nevertheless, it remains rare, as it represents 1% of all malignancies affecting the male population. Often, patients present with nonspecific conditions, such as painless testicular mass or scrotal edema, but may describe signs of more advanced disease such as inguinal adenopathies or symptoms of metastatic pulmonary lesions. Treatment is often a combination of bilateral orchidectomy, chemotherapy, and radiotherapy. The current 5-year survival rate with treatment is 97%.1,2

Exposure to exogenous hormones may increase one’s lifetime risk of developing gonadal cancer.3 Excessive circulating estrogen may alter testicular parenchyma similarly to testicular dysgenesis syndrome—a predisposing condition to testicular cancer.4 This potential adverse effect is of particular importance in the transfeminine population, as transitioning often implies a prolonged intake of estrogen, consequently resulting in more frequent use of hormonal therapy.5 Known risk factors for the development of testicular cancer include life habits, family history, and genetic factors; however, no study has proposed evidence that links testicular cancer to exogenous estrogen intake.6 Further research is necessary to determine if hormonotherapy may be a driver of malignancy in the cases of testicular neoplasia.

We conducted a retrospective study to elucidate the percentage of incidental findings of testicular cancer in transfeminine patients who underwent gender-affirming surgery at our institution. A secondary goal was to contribute to the paucity of literature on this subject.

METHODS

A retrospective review of transgender patients undergoing vaginoplasty with orchidectomy at our institution was completed. All cases between 2016 and 2020 were examined to report the number of positive instances of testicular cancer. Only six cases have been reported in the literature. This case series reports six additional cases of various testicular cancers found in transfeminine patients who underwent vaginoplasty with orchidectomy in our institution.

RESULTS

A total of 2555 patients underwent vaginoplasty with orchidectomy at our institution between January 2016 and January 2021. All specimens were sent to pathology for analysis. A total of six (0.23% of patients) specimens revealed malignant lesions.

CONCLUSIONS

Increased societal awareness toward the transgender population encourages recourse to gender-affirming procedures. Little is known about the incidence of testicular cancer in the transfeminine population. In total, 0.23% of patients in our cohort presented with positive pathology findings indicative of testicular cancer. All cancers were found to be only locally invasive, and all patients were successfully treated. We therefore encourage routine pathology examination for all specimens following vaginoplasty with orchidectomy. (Plast Reconstr Surg Glob Open 2022;10:e4051; doi: 10.1097/GOX.0000000000004051; Published online 18 April 2022.)
age, BMI, smoking status), duration of hormonotherapy, type of neoplasm, the context of its discovery, and modalities of cancer evaluation. The study was conducted in compliance with the principles of the Declaration of Helsinki.

RESULTS

A total of 2555 patients underwent vaginoplasty with orchidectomy between January 2016 and January 2021. All specimens were sent to pathology for analysis. Of all the submitted specimens for routine examination, six (0.23% of patients) revealed malignant lesions. All of these patients were asymptomatic preoperatively. Of these six malignant lesions, three were seminomas and three were intratubular germ cell neoplasia. Malignant changes in all the collected specimens did not extend beyond the basement membrane. All patients were referred to urology for appropriate workup, which revealed only locally invasive lesions (T1N0M0) in all cases.

For patients with positive pathology, the average age at the time of the surgery was 27.7 years (range 16–48) and all patients were on hormonotherapy (average 3.5 years, range 2–6). The average BMI was 24.4 ± 5.6, and one patient had a positive personal history of tobacco use. No patients had a personal or familial history of testicular cancer (Table 1).

DISCUSSION

Our retrospective review revealed six incidental findings of testicular cancer in asymptomatic transfeminine patients undergoing vaginoplasty with orchidectomy. This represents 0.23% of our patient population. Only six other cases of testicular cancer in transfeminine patients have been reported in the literature. In these studies, four of the six patients had clinical manifestations of the tumor, whereas the other two cases were incidental findings after a gender-affirming surgery involving orchidectomy. Five of these patients had locally invasive disease, whereas one had metastatic disease (Table 2).

Table 1. Patient Demographics and Pathology Results

| Year | Patient Age | BMI | Tobacco Use | Years of HRT* | Symptoms | Pathology | Staging |
|------|-------------|-----|-------------|--------------|----------|----------|---------|
| 2021 | 26          | 31.9| Yes         | 3            | None     | 8-mm seminoma | Locally invasive pT1N0M0 |
| 2018 | 20          | 19.6| No          | 6            | None     | Intratubular germ cell neoplasia and microscopic intertubular seminoma cells | Locally invasive pT1N0M0 |
| 2019 | 22          | 16.5| No          | 4            | None     | Intratubular germ cell neoplasia | Locally invasive pT1N0M0 |
| 2019 | 31          | 27.2| No          | 2            | None     | 5-mm seminoma | Locally invasive pT1N0M0 |
| 2018 | 19          | 26.6| No          | 3            | None     | Intratubular germ cell neoplasia | Locally invasive pT1N0M0 |
| 2016 | 48          | 25.8| No          | 3            | None     | 1-cm seminoma | Locally invasive pT1N0M0 |

*HRT, hormonal replacement therapy.

Table 2. Reported Cases of Testicular Cancer

| Authors | Year | Patient Age | Years of HRT* | Symptoms | Pathology | Staging |
|---------|------|-------------|---------------|----------|-----------|---------|
| Jacoby et al<sup>10</sup> | 2021 | 29          | Yes           | Persistence of masculine characteristics and failure to suppress testosterone despite hormonotherapy | Germ cell tumor with embryologic and yolk sac components 3.1 × 3.1 × 2.3 cm hCG-secreting seminoma | Locally invasive pT1N0M0 |
| Elshimy et al<sup>11</sup> | 2020 | 31          | >1            | None     | 2.1-cm seminoma | Locally invasive pT1b, Nx, M0 |
| Khach et al<sup>9</sup> | 2019 | 30          | 1.75          | Right-sided scrotal swelling, abdominal and back pain, fatigue, and weight loss of 7 kg | Germ cell tumor | Locally invasive 1A |
| Chandhoke et al<sup>4</sup> | 2018 | 38          | 1.25          | Persistence of masculine characteristics and failure to suppress testosterone despite hormonotherapy | Germ cell tumor with embryonal carcinoma (75%), immature teratoma, seminoma (9%), and yolk sac tumor (<1%) | Locally invasive Stage 1 T2N0M0 |
| Wolf-Gould and Wolf-Gould<sup>12</sup> | 2016 | 28          | 2             | Testicular mass | Testicular teratoma | Locally invasive |
| Kobori et al<sup>8</sup> | 2015 | 30          | 2             | Testicular mass | | |

*HRT, hormonal replacement therapy.
To this day, evidence describing the effect of estrogenic hormonotherapy on the testicular matrix remains sparse and inconclusive. Some studies bring forth a theoretical risk of testicular cancer with exogenous hormonotherapy.\(^5,13\) Excessive circulating estrogen leads to the remodeling of testicular parenchyma by acting on endocrinological pathways. These subsequent histological changes are similar to those found in patients with testicular dysgenesis syndrome—a known risk factor for testicular neoplasia.\(^5\) However, a recent retrospective study examined 135 specimens from transfeminine patients who had an orchidectomy, of which 75.6% (102/135) had been on hormonotherapy. No specimens displayed premalignant or malignant histologic changes.\(^14\)

The current Endocrine Society’s guideline regarding the treatment of gender-dysphoric and gender incongruent individuals does not recommend routine screening tests for testicular cancer in the transfeminine population. These current recommendations are the same as those offered to the cisgender population.\(^15\) However, there are no recommendations regarding best practices for pathology post orchidectomy. More research is needed to determine if there exists a link between exogenous hormonotherapy in transfeminine patients and the risk of developing testicular cancer. Limitations of this article include its retrospective and unicentric nature.

**CONCLUSIONS**

The growing societal acceptance of the transgender population has led to increased demand and access to gender-affirming procedures.\(^6\) Over the last 5 years, six transfeminine patients were found to have testicular cancer on routine pathology examination following vaginoplasty with orchidectomy in our institution. We therefore will continue the routine pathology examination for all specimens following vaginoplasty with orchidectomy.

Maud Bélanger, MD, FRCSC  
Centre Métropolitain de Chirurgie  
999 Rue de Salaberry  
Montréal, Québec  
Canada H3L 1K8  
E-mail: mbelanger@grsmontreal.com

**REFERENCES**

1. Brenner DR, Heer E, Ruan Y, et al. The rising incidence of testicular cancer among young men in Canada, data from 1971–2015. *Cancer Epidemiol.* 2019;58:175–177.
2. Gilligan T. Testicular cancer survivorship. *Hematol Oncol Clin North Am.* 2011;25:627–39.
3. Smith ZL, Werntz RP, Eggener SE. Testicular cancer: epidemiology, diagnosis, and management. *Med Clin North Am.* 2018;102:251–264.
4. Chandeloke G, Shayaeghan B, Hotte SJ. Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: a case report. *J Med Case Rep.* 2018;12:373.
5. Nistal M, González-Peramato P, De Miguel MP. Sertoli cell dedifferentiation in human cryptorchidism and gender reassignment shows similarities between fetal environmental and adult medical treatment estrogen and antiandrogen exposure. *Reprod Toxicol.* 2013;42:172–179.
6. Zucker KJ. Epidemiology of gender dysphoria and transgender identity. *Sex Health.* 2017;14:404–411.
7. de Blok CJM, Dreijerink KMA, den Heijer M. Cancer risk in transgender people. *Endocrinol Metab Clin North Am.* 2019;48:441–452.
8. Kobori Y, Suzuki K, Iwahata T, et al. Mature testicular teratoma with positive estrogen receptor beta expression in a transdermed individual on cross-sex hormonal therapy: a case report. *LGBT Health.* 2015;2:81–83.
9. Kvach EJ, Hyer JS, Carey JC, et al. Testicular seminoma in a transgender woman: a case report. *LGBT Health.* 2019;6:40–42.
10. Jacoby A, Rékin W, Zhao LC, et al. Incidence of cancer and premalignant lesions in surgical specimens of transgender patients. *Plast Reconstr Surg.* 2021;147:194–198.
11. Eshimy G, Tran K, Harman SM, et al. Unmasked testicular seminoma during use of hormonal transgender woman therapy: a hidden hCG-secreting tumor. *J Endocr Soc.* 2020;4:bvaa074.
12. Wolf-Gould CS, Wolf-Gould CH. A transgender woman with testicular cancer: a new twist on an old problem. *LGBT Health.* 2016;3:90–95.
13. Nistal M, Pastrián LG, González-Peramato P, et al. Inhibin bodies: a new marker for immature Sertoli cells. *Histopathology.* 2011;58:1019–1027.
14. Kent MA, Winoker JS, Grotas AB. Effects of feminizing hormones on sperm production and malignant changes: microscopic examination of post orchietomy specimens in transwomen. *Urology.* 2018;121:93–96.
15. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2017;102:3869–3903.